MUC1 and cancer: Given the cancer immunoprevention potential of the MUC1 peptide vaccine response, characterized by a reduction of adenoma recurrence (15), the differentially expressed genes and regulated pathways we identified hold promise as therapeutic targets for vaccine non-responders.